Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JP, Mann J, Tuttle KR, Idorn T, Rathor N, Lincoff AM (2024)

Publication Type: Journal article

Publication year: 2024

Journal

Nature Medicine Nature Publishing Group

DOI: 10.1038/s41591-024-03015-5

Abstract

The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min−1 1.73 m−2, persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02. The treatment benefit at 104 weeks for eGFR was 0.75 ml min−1 1.73 m−2 (95% CI 0.43, 1.06; P < 0.001) overall and 2.19 ml min−1 1.73 m−2 (95% CI 1.00, 3.38; P < 0.001) in patients with baseline eGFR <60 ml min−1 1.73 m−2. These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes. ClinicalTrials.gov identifier: NCT03574597.

Involved external institutions

University of Edinburgh GB United Kingdom (GB) University of Texas Southwestern Medical Center (UT Southwestern) US United States (USA) (US) Novo Nordisk A/S DK Denmark (DK) University College London (UCL) GB United Kingdom (GB) University of Washington US United States (USA) (US) Veterans Affairs Healthcare System Boston and Harvard Medical School US United States (USA) (US) Saga University JP Japan (JP) M.D. Strazhesko Institute of Cardiology UA Ukraine (UA) Karolinska Institute SE Sweden (SE) The University of Liverpool GB United Kingdom (GB) Case Western Reserve University US United States (USA) (US)

How to cite

APA:

Colhoun, H.M., Lingvay, I., Brown, P.M., Deanfield, J., Brown-Frandsen, K., Kahn, S.E.,... Lincoff, A.M. (2024). Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03015-5

MLA:

Colhoun, Helen M., et al. "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial." Nature Medicine (2024).

BibTeX: Download